SK plasma, a Korean company specializing in plasma derivatives, said Monday that it has signed an exclusive domestic distribution agreement with Janssen Korea, the pharmaceutical division of Johnson & Johnson.
The agreement covers the Velcade injection (bortezomib triple complex), a treatment for multiple myeloma and mantle cell lymphoma.
Under the agreement, Janssen Korea will manufacture and supply Velcade, while SK plasma will oversee domestic distribution and marketing.
The deal expands SK plasma’s blood cancer treatment portfolio, adding Velcade for multiple myeloma and malignant lymphoma to its existing product lineup, which includes Dacogen (decitabine), a treatment for myelodysplastic syndrome and acute myeloid leukemia.
“This agreement not only strengthens our oncology portfolio but also enables us to provide a widely recognized standard therapy for multiple myeloma patients,” said Kim Seung-joo, CEO of SK plasma.
In 2023, SK plasma secured exclusive domestic rights to market Janssen Korea’s Dacogen, an anti-cancer drug used to treat myelodysplastic syndrome and acute myeloid leukemia. The company has been actively marketing the product since then.
Related articles
- Merck's Tepmetko, GSK-Janssen's Vocabria+Rekambys combo move closer to reimbursement in Korea
- SK plasma secures investment from Indonesia's sovereign wealth fund, plans blood product plant to boost self-sufficiency
- Johnson & Johnson appoints Christian Rodseth as North Asia pharma head
- Janssen's bispecific antibody drug for multiple myeloma wins nod in Korea
- SK plasma receives 1st batch of Indonesian plasma for local CMO production
- SK plasma enters ADC cancer drug development with AimedBio partnership